Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01066546 · ClinicalTrials.gov registry record · Phase 3
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT01066546: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT01066546 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 5 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01066546, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of dimebon in subjects with moderate-to-severe Alzheimer's Disease.
Primary Outcome
An adverse event is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Interventions
- DRUG Dimebon tablet for oral administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Why NCT01066546 stopped before completion
NCT01066546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Dimebon tablet for oral administration is the first listed.
NCT01066546 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01066546 about?
NCT01066546 is a clinical study titled "An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease". The purpose of this study is to evaluate the long-term safety and tolerability of dimebon in subjects with moderate-to-severe Alzheimer's Disease.
What is the current status of trial NCT01066546?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2010-04. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01066546?
The interventions under investigation include: Dimebon tablet for oral administration (DRUG).
Who is sponsoring clinical trial NCT01066546?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01066546's enrollment target sits among peer trials
5 1997th of 2000 higher than 3 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia